Last updated: June 17, 2026
Executive summary
Ascendis Pharma A/S has filed suit against BioMarin Pharmaceutical Inc. in the District of New Jersey (case caption “Ascendis Pharma A/S v. BioMarin Pharmaceutical Inc.”, No. 4:25-cv-05696). The case number places the matter in the “2025” cohort and indicates active, current IP enforcement. A litigation summary and infringement/patent portfolio analysis cannot be produced from the case identifier alone because the complaint, asserted patent numbers, defendants’ product identification, requested relief, and procedural posture are not provided.
What is the Ascendis v. BioMarin case 4:25-cv-05696 about?
Featured snippet answer: The case is newly filed in 2025 and is pending in the District of New Jersey, but the dispute subject matter (asserted patents, product(s) at issue, and claims) is not determinable from the docket number alone.
Who are the parties and what role does each play?
- Plaintiff: Ascendis Pharma A/S
- Defendant: BioMarin Pharmaceutical Inc.
- Court: U.S. District Court (District of New Jersey)
- Case number: 4:25-cv-05696
What type of IP dispute does the caption suggest?
The caption does not specify the IP regime (e.g., Hatch-Waxman patent infringement, biologics/BPCIA, trade secret, or method-of-use). A litigation analysis requires the asserted patent claims and the regulatory context (e.g., ANDA/BLA pathway and Paragraph IV or counterpart filings), which are not available in the prompt.
Which patents are asserted in Ascendis Pharma A/S v. BioMarin Pharmaceutical Inc. 4:25-cv-05696?
Featured snippet answer: Not identifiable from the case number alone.
What you need to map for infringement analysis
A patent estate and risk assessment must enumerate:
- Asserted U.S. patent numbers
- Assignees and any assignment chain issues
- Claim categories (composition, formulation, method of use, manufacturing)
- Priority dates and prosecution history markers (relevant to non-obviousness)
- Whether patents are listed in the Orange Book (if ANDA/Hatch-Waxman) or tethered to biologics reference product exclusivity (if BLA/BPCIA)
No such patent identifiers are present in the prompt.
Is this a Paragraph IV Hatch-Waxman case or a BPCIA dispute?
Featured snippet answer: Unknown based on 4:25-cv-05696 alone.
Why the regulatory pathway drives the litigation posture
- Hatch-Waxman (ANDA) typically aligns with Orange Book listing, 30-month stay, and Paragraph IV notices.
- BPCIA (BLA) typically aligns with Biosimilar procedural steps (notice of commercial marketing, patent lists, exchanges, and venue/threshold issues).
Without the complaint or docket entries, the pathway cannot be confirmed and the correct litigation framework cannot be applied.
What does Ascendis claim BioMarin infringes in this lawsuit?
Featured snippet answer: The infringement theory and the accused product cannot be determined from the case number alone.
What infringement mapping usually includes
A complete litigation summary normally details:
- Accused drug product name(s) and dosage forms
- The specific asserted claims and claim charts
- Alleged bases for infringement (direct, induced, contributory)
- Equitable factors raised (willfulness, irreparable harm, lack of adequate remedy)
- Enhanced damages and marking theories (if pleaded)
No complaint allegations are available here.
What is the current procedural status for 4:25-cv-05696 (motions, injunctions, deadlines)?
Featured snippet answer: Not determinable from the case number alone.
Typical status milestones to report
- Filing and service dates
- Initial case management order
- Scheduling order and claim construction deadlines
- Motions to dismiss (Rule 12), for summary judgment, to strike, or for preliminary injunction
- Markman hearing schedule (if needed)
- Any PTAB estoppel events tied to validity challenges
These docket facts are not in the prompt, so a status-based analysis would be incomplete.
How strong is the patent estate behind the Ascendis complaint in this case?
Featured snippet answer: Not assessable without the asserted patents and claim scope.
How strength is typically evaluated for litigation decisions
- Claim breadth vs. prior art risk
- Written description and enablement vulnerabilities
- Obviousness and anticipation exposure
- Prior litigation outcomes involving overlapping claim scope
- Potential for non-infringement defenses based on product differences
None of these inputs are present.
What generic entry risks exist for the drug targeted by Ascendis in 4:25-cv-05696?
Featured snippet answer: Generic entry risk depends on exclusivity expirations and the regulatory filing strategy, which are not identifiable from 4:25-cv-05696 alone.
Risk model inputs normally required
- Which reference product is implicated
- Orange Book expiration (patent term) and exclusivity (market exclusivity)
- Whether the defendant is pursuing ANDA with Paragraph IV certifications
- Potential 30-month stay timeline and launch triggers
- Settlement constraints (Agreements affecting launch dates)
No such details are available.
How does this case compare with other Ascendis vs. BioMarin patent disputes?
Featured snippet answer: Cannot be compared without knowing the asserted patents, drug(s) at issue, and outcome history.
What a comparative analysis requires
- Prior cases’ docket numbers
- Overlapping patent families and claim strategies
- Win/loss outcomes and damages or injunction terms
- Settlement terms and product launch impacts
No comparative set is supplied.
What is the Orange Book status of the patents at issue in Ascendis v. BioMarin 4:25-cv-05696?
Featured snippet answer: Not determinable from the prompt.
What should be checked in Orange Book-driven cases
For each asserted U.S. patent:
- Whether it is listed for the specific NDA
- Patent expiry date(s)
- Exclusivity type (12-year drug, 6-year, pediatric, orphan, system exclusivities)
- Any delistings or expiration changes
The NDA/NDC and asserted patents are not provided.
Does the lawsuit target a biologic or an injectable delivery system protected by formulation or method claims?
Featured snippet answer: Unknown from the case identifier alone.
Common delivery-system and method-of-use claim patterns
In endocrine and growth-related therapeutics, disputes often involve:
- Long-acting formulation/molecular modifications
- Dosing regimens and method-of-use claims
- Manufacturing changes affecting functional properties
Without the asserted claims, the question cannot be answered.
What settlements or injunction outcomes are known for 4:25-cv-05696?
Featured snippet answer: No settlement or injunction outcomes can be stated from the prompt.
Settlement terms that matter to business planning
- License scope and royalty structure
- Design-around commitments
- Launch date covenants and mutual dismissal provisions
- Ongoing exclusivity waivers or patent sublicensing
No terms are included.
Key Takeaways
- Case identification: Ascendis Pharma A/S v. BioMarin Pharmaceutical Inc., 4:25-cv-05696 in the District of New Jersey.
- Current limitation: A litigation summary and patent-risk analysis cannot be produced without the asserted patent numbers, accused product, claim basis, and procedural docket events.
- Decision impact: The absence of asserted-patent and Orange Book/BLA linkage prevents a defensible exclusivity and generic entry risk assessment.
FAQs
- What is the difference between a Hatch-Waxman Paragraph IV case and a BPCIA biosimilar case in infringement strategy?
- How do courts in the District of New Jersey typically schedule Markman hearings for early patent cases?
- What factors drive irreparable harm findings in pharma patent injunction motions?
- How do license settlements usually structure royalty and launch covenants in pharma patent disputes?
- How does Orange Book listing determine whether an ANDA challenger is exposed to a 30-month stay?
References
- Ascendis Pharma A/S v. BioMarin Pharmaceutical Inc., Case No. 4:25-cv-05696 (D.N.J. 2025).
